Kura Oncology, Inc. $KURA Shares Acquired by Pale Fire Capital SE

Pale Fire Capital SE increased its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 89.6% during the first quarter, HoldingsChannel reports. The firm owned 857,474 shares of the company’s stock after acquiring an additional 405,229 shares during the period. Kura Oncology accounts for approximately 0.6% of Pale Fire Capital SE’s holdings, making the stock its 19th biggest position. Pale Fire Capital SE’s holdings in Kura Oncology were worth $6,971,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. State Street Corp raised its holdings in shares of Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after acquiring an additional 1,587,959 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in shares of Kura Oncology by 101.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after acquiring an additional 1,121,228 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Kura Oncology by 111.6% in the 4th quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after purchasing an additional 965,256 shares during the period. AQR Capital Management LLC boosted its stake in Kura Oncology by 36.6% in the 4th quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after purchasing an additional 820,020 shares during the period. Finally, Qube Research & Technologies Ltd grew its position in Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after purchasing an additional 738,761 shares in the last quarter.

Insider Transactions at Kura Oncology

In other news, insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider owned 182,345 shares in the company, valued at approximately $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 7.60% of the stock is owned by corporate insiders.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $10.39 on Friday. The firm has a fifty day simple moving average of $10.28 and a 200-day simple moving average of $9.28. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. Kura Oncology, Inc. has a 1-year low of $5.45 and a 1-year high of $12.49. The stock has a market capitalization of $922.32 million, a price-to-earnings ratio of -3.10 and a beta of 0.35.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.05. The company had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%. On average, sell-side analysts expect that Kura Oncology, Inc. will post -3.45 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on KURA shares. CLSA set a $24.00 price target on Kura Oncology in a research report on Thursday, June 4th. Citizens Jmp restated a “market outperform” rating and set a $24.00 price objective on shares of Kura Oncology in a research report on Monday, June 15th. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a research note on Monday, June 15th. Lake Street Capital began coverage on Kura Oncology in a report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 target price on the stock. Finally, Citigroup reissued a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and an average target price of $25.46.

Kura Oncology Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.